These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37561283)

  • 1. Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review.
    Toledo T; Castro T; Oliveira VG; Veloso VG; Grinsztejn B; Cardoso SW; Torres TS; Estrela R
    Clin Pharmacokinet; 2023 Sep; 62(9):1219-1230. PubMed ID: 37561283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
    Salama E; Hill L; Patel N; Best BM; Momper JD
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):389-392. PubMed ID: 34285156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
    Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
    J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
    Mogalian E; Stamm LM; Osinusi A; Brainard DM; Shen G; Ling KHJ; Mathias A
    Clin Infect Dis; 2018 Aug; 67(6):934-940. PubMed ID: 29522076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Coencapsulated Antiretrovirals with Ingestible Sensors.
    Liu H; Daar E; Wang Y; Siqueiros L; Campbell K; Shen J; Guerrero M; Ko MW; Xiong D; Dao J; Young T; Rosen M; Fletcher CV
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):65-74. PubMed ID: 31516025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up.
    Calza L; Borderi M; Colangeli V; Borioni A; Coladonato S; Granozzi B; Viale P
    Infect Dis (Lond); 2020 Apr; 52(4):249-256. PubMed ID: 31876437
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.
    Bracchi M; Pagani N; Dalla Pria A; Milinkovic A; Nwokolo N; Thomas L; Mandalia S; Boffito M; Moyle G
    HIV Res Clin Pract; 2021 Oct; 22(5):128-139. PubMed ID: 34551678
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals.
    Begley R; Das M; Zhong L; Ling J; Kearney BP; Custodio JM
    J Acquir Immune Defic Syndr; 2018 Aug; 78(4):465-472. PubMed ID: 29649076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
    Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
    AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
    Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The maraviroc expanded access program - safety and efficacy data from an open-label study.
    Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
    HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.
    Aebi-Popp K; Kahlert CR; Crisinel PA; Decosterd L; Saldanha SA; Hoesli I; Martinez De Tejada B; Duppenthaler A; Rauch A; Marzolini C;
    J Antimicrob Chemother; 2022 Nov; 77(12):3436-3442. PubMed ID: 36177836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
    Squillace N; Bozzi G; Colella E; Gori A; Bandera A
    Drug Des Devel Ther; 2018; 12():3635-3643. PubMed ID: 30464395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
    Hsu RK; Brunet L; Fusco JS; Mounzer K; Lamori JC; Fusco GP
    AIDS Res Hum Retroviruses; 2022 Oct; 38(10):782-791. PubMed ID: 35923143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
    Grau S; Miró JM; Olalla J; Alcalá JC; Castro A; Rubio-Rodríguez D; Rubio-Terrés C
    Expert Rev Anti Infect Ther; 2023 Jan; 21(1):65-76. PubMed ID: 36399521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
    Crauwels HM; Baugh B; Van Landuyt E; Vanveggel S; Hijzen A; Opsomer M
    Clin Pharmacol Drug Dev; 2019 May; 8(4):480-491. PubMed ID: 30412360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.
    Tashima KT; Mollan KR; Na L; Gandhi RT; Klingman KL; Fichtenbaum CJ; Andrade A; Johnson VA; Eron JJ; Smeaton L; Haubrich RH
    HIV Clin Trials; 2015 Aug; 16(4):147-56. PubMed ID: 26212575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
    Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
    Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy and liver disorders in the OPERA
    Wohlfeiler M; Mounzer K; Brunet L; Fusco J; Vannappagari V; Curtis L; Payvandi N; Aboud M; Hsu R; Lackey P; Fusco G
    Ther Adv Drug Saf; 2020; 11():2042098620976953. PubMed ID: 33343858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.